Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Intervalo de año de publicación
1.
Trans R Soc Trop Med Hyg ; 100(7): 642-9, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16274713

RESUMEN

Controlled heat delivered as radio waves has been used successfully in the treatment of cutaneous leishmaniasis (CL). Here we investigated whether local heat therapy has systemic effects, as measured by the modulation of cytokine production following heat therapy of CL lesions compared with antimonial (Glucantime) treatment. Patients with CL were randomly assigned into this study. Heat (50 degrees C for 30s) was applied once. The control group received Glucantime therapy for 20 d. Cytokine production by peripheral blood mononuclear cells was assayed on days 0, 14 and 28 after onset of treatment. At the end of 28 d, 75% of lesions were healing or healed in the heat therapy group and 90% in the control group (P=0.1261). There was a decrease in IFN-gamma, IL-5 and TNF-alpha levels comparing day 0 with day 28 in both groups, but no difference between the two therapy groups. In patients with only one of several lesions treated with heat therapy, the untreated lesions also healed. Local heat therapy in CL lesions leads to systemic cytokine responses similar to that induced by systemic Glucantime therapy.


Asunto(s)
Antiprotozoarios/uso terapéutico , Citocinas/metabolismo , Calor/uso terapéutico , Leishmaniasis Cutánea/terapia , Meglumina/uso terapéutico , Compuestos Organometálicos/uso terapéutico , Adolescente , Adulto , Anciano , Femenino , Humanos , Interferón gamma/metabolismo , Interleucina-10/metabolismo , Interleucina-5/metabolismo , Leishmaniasis Cutánea/tratamiento farmacológico , Leishmaniasis Cutánea/inmunología , Leucocitos Mononucleares/inmunología , Masculino , Antimoniato de Meglumina , Persona de Mediana Edad , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/metabolismo
2.
Arq. bras. med ; 66(1): 67-71, jan.-fev. 1992. tab
Artículo en Portugués | LILACS | ID: lil-228170

RESUMEN

Aztreonam é um composto de uma nova classe de agentes Beta-lactâmicos monocíclicos sintéticos com atividade contra a grande maioria das bactérias Gram-negativas, mas nao contra as bactérias Gram-positivas ou anaeróbias. Aztreonam foi usado para tratar 23 pacientes com importantes infeccçoes por germes Gram-negativos. Neste estudo dos 17 homens e seis mulheres, haviam 11 casos de infecçoes urinárias, três de pneumonia, três de meningite e seis com outros locais de infecçao. Noventa por cento das infecçoes foram curadas tanto por critérios clínicos como microbiológicos sem significantes reaçoes adversas ou toxicidade pela droga.


Asunto(s)
Humanos , Masculino , Femenino , Aztreonam/uso terapéutico , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Monobactamas/uso terapéutico , Estudios Prospectivos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...